Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of treprostinil palmitil inhalation powder in pulmonary hypertension associated with interstitial lung disease
jRCT2031260197Recruiting
- Sponsor
- Insmed Incorporated
- Start
- Jul 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 2
01
Overview
Open-label, single-arm trial of treprostinil palmitil in pulmonary hypertension associated with interstitial lung disease (PH-ILD), sponsored by Insmed Incorporated. Primary endpoint: Number of participants with at least one treatment-emergent adverse event. Started Jul 2026; status: recruiting.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on jRCT2031260197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260197.